These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 14765334)
1. [Underutilization of cardiovascular pharmacotherapy: how to pay for it?]. Wehling M Dtsch Med Wochenschr; 2004 Feb; 129(7):330. PubMed ID: 14765334 [No Abstract] [Full Text] [Related]
2. Drug treatment and cost of cardiovascular disease in Australia. Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C; Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615 [TBL] [Abstract][Full Text] [Related]
3. Reducing drug usage and adverse effects. Part III: Cardiovascular disease and hyperlipidemia. Baron M Health Care Food Nutr Focus; 2005 Jun; 22(6):7-11. PubMed ID: 15923907 [No Abstract] [Full Text] [Related]
6. Letter by Kelland and Roberts regarding article, "Lipid management to reduce cardiovascular risk: a new strategy is required". Kelland NF; Roberts AP Circulation; 2008 Aug; 118(7):e119. PubMed ID: 18695198 [No Abstract] [Full Text] [Related]
7. [Methods of evaluating drug therapy, particularly in cardiovascular diseases]. Lövy O; Toman J Cesk Zdrav; 1984 Sep; 32(8-9):361-5. PubMed ID: 6509673 [No Abstract] [Full Text] [Related]
9. [Secondary nutritional and drug prevention of cardiovasculopathies]. Comi D; Comi AL Recenti Prog Med; 1999 Mar; 90(3):155-9. PubMed ID: 10228356 [No Abstract] [Full Text] [Related]
10. [Lipid and blood pressure reduction for reduction of cardiovascular mortality]. Heinzl S Med Monatsschr Pharm; 2003 Jun; 26(6):185. PubMed ID: 12840952 [No Abstract] [Full Text] [Related]
11. [Pharmacological need and pharmacological economy in cardiology]. Garattini S G Ital Cardiol; 1997 Dec; 27(12):1315-8. PubMed ID: 9470067 [No Abstract] [Full Text] [Related]
12. Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk. Rafter N; Connor J; Hall J; Jackson R; Martin I; Parag V; Vander Hoorn S; Rodgers A N Z Med J; 2005 Oct; 118(1223):U1676. PubMed ID: 16224500 [TBL] [Abstract][Full Text] [Related]
14. Increase in lipid-lowering treatment rates among TRICARE beneficiaries: a population-based study. Devine J; Linton A; Mistry H; Napier J; Trice S; Bacon T Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):891-9. PubMed ID: 19634117 [TBL] [Abstract][Full Text] [Related]
15. Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of available ones. Shantsila A; Lip GY Int J Clin Pract; 2010 Jan; 64(2):138-40. PubMed ID: 20089004 [No Abstract] [Full Text] [Related]
16. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Staels B; Maes M; Zambon A Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776 [TBL] [Abstract][Full Text] [Related]
17. Suboptimal use of cardioprotective drugs in newly treated elderly individuals with type 2 diabetes. Sirois C; Moisan J; Poirier P; Grégoire JP Diabetes Care; 2007 Jul; 30(7):1880-2. PubMed ID: 17384345 [No Abstract] [Full Text] [Related]
18. Dramatic proposal to reduce CVD sparks new focus on DM alternatives. Dis Manag Advis; 2004 Jun; 10(6):66-8, 61. PubMed ID: 15328751 [TBL] [Abstract][Full Text] [Related]
19. [Statins in practice of the vascular surgeon and cardiologist]. Pokrovskiĭ AV; Suntsov DS Angiol Sosud Khir; 2009; 15(2):123-7. PubMed ID: 19806952 [TBL] [Abstract][Full Text] [Related]